Grifols S.A. ADR Stock
Pros and Cons of Grifols S.A. ADR in the next few years
Pros
?
M***** P*******
?
S********** s********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Grifols S.A. ADR vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Grifols S.A. ADR | 2.610% | 3.509% | -7.087% | -12.593% | -36.216% | -60.087% | -64.881% |
Beximco Pharmaceuticals Ltd. GDR | - | -2.326% | -4.545% | -10.256% | -4.545% | -53.333% | -24.324% |
Cellectar BioSciences Inc. | 2.560% | 11.972% | -13.587% | 127.143% | 39.474% | -75.156% | - |
SELLAS Life Sciences Group Inc | -2.710% | -10.147% | 1.327% | -7.143% | 25.333% | -81.200% | -99.667% |
Comments
Grifols, S.A. (NASDAQ: GRFS) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "sell" rating.
Show more
Ratings data for GRFS provided by MarketBeat